Associated Papers
MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation.
Guérin C et al.
Molecular Oncology, 2025
MET variants with activating N-lobe mutations identified in hereditary papillary renal cell carcinomas still require ligand stimulation.
Guérin C et al.
Biorxiv : the Preprint Server for Biology, 2025
Homozygous CCDC146 mutation causes oligoasthenoteratozoospermia in humans and mice.
Ye JW et al.
Zoological Research, 2024
39245651 (PubMed )
Supplement: zr-45-1073-S1.pdf
A Case Study on PPM1D and 9 Other Shared Germline Alterations in a Family.
Biswas S et al.
Asian Pacific Journal of Cancer Prevention : Apjcp, 2023
Novel germline MET pathogenic variants in French patients with papillary renal cell carcinomas type I.
Sebai M et al.
Human Mutation, 2022
Genomics of lethal prostate cancer at diagnosis and castration resistance.
Mateo J et al.
The Journal of Clinical Investigation, 2020
31874108 (PubMed )
Supplement: jci-130-132031-s100.xlsx › Sheet1
Germline mutations in candidate predisposition genes in individuals with cutaneous melanoma and at least two independent additional primary cancers.
Pritchard AL et al.
Plos One, 2018
29641532 (PubMed )
Supplement: pone.0194098.s003.xlsx › UK10K_Kinase_
Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.
Choueiri TK et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 2017
Select a paper to view details